India Washington
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
India Washington has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Birginia Espinoza
Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center
1 shared publication - Haley Zlomke
Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center
1 shared publication - Heng-Chung Kung
Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center
1 shared publication - Jianxin Wang
Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center
1 shared publication - Juan Fu
Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center
1 shared publication - Kai Chen
Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center
1 shared publication
Latest Publications
- Open Access
- 8 November 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (21)
Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion
The dual tumor-suppressive and -promoting functions of TGF-β signaling has made its targeting challenging. We examined the effects of TGF-β depletion by AVID200/BMS-986416 (TGF-β-TRAP), a TGF-β ligand trap, on the tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) murine models with different organ-specific metastasis. Our study demonstrated that TGF-β-TRAP potentiates the efficacy of anti–programmed cell death 1 (anti–PD-1) in a PDAC orthotopic murine model with liver metastasis tropism, significantly reducing liver metastases. We further demonstrated the heterogeneous response of cytotoxic effector T cells to combination TGF-β-TRAP and anti–PD-1 treatment across several tumor models. Single-nuclear RNA sequencing suggested that TGF-β-TRAP modulates cancer-associated fibroblast (CAF) heterogeneity and suppresses neutrophil degranulation and CD4 + T cell response to neutrophil degranulation. Ligand-receptor analysis indicated that TGF-β-TRAP may modulate the CCL5/CCR5 axis as well as costimulatory and checkpoint signaling from CAFs and myeloid cells. Notably, the most highly expressed ligands of CCR5 shifted from the immunosuppressive CCL5 to CCL7 and CCL8, which may mediate the immune agonist activity of CCR5 following TGF-β-TRAP and anti–PD-1 combination treatment. This study suggested that TGF-β depletion modulates CAF heterogeneity and potentially reprograms CAFs and myeloid cells into antitumor immune agonists in PDAC, supporting the validation of such effects in human specimens.
- 8 November 2024
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 9 (21)
Open AccessTargeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion
The dual tumor-suppressive and -promoting functions of TGF-β signaling has made its targeting challenging. We examined the effects of TGF-β depletion by AVID200/BMS-986416 (TGF-β-TRAP), a TGF-β ligand trap, on the tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) murine models with different organ-specific metastasis. Our study demonstrated that TGF-β-TRAP potentiates the efficacy of anti–programmed cell death 1 (anti–PD-1) in a PDAC orthotopic murine model with liver metastasis tropism, significantly reducing liver metastases. We further demonstrated the heterogeneous response of cytotoxic effector T cells to combination TGF-β-TRAP and anti–PD-1 treatment across several tumor models. Single-nuclear RNA sequencing suggested that TGF-β-TRAP modulates cancer-associated fibroblast (CAF) heterogeneity and suppresses neutrophil degranulation and CD4 + T cell response to neutrophil degranulation. Ligand-receptor analysis indicated that TGF-β-TRAP may modulate the CCL5/CCR5 axis as well as costimulatory and checkpoint signaling from CAFs and myeloid cells. Notably, the most highly expressed ligands of CCR5 shifted from the immunosuppressive CCL5 to CCL7 and CCL8, which may mediate the immune agonist activity of CCR5 following TGF-β-TRAP and anti–PD-1 combination treatment. This study suggested that TGF-β depletion modulates CAF heterogeneity and potentially reprograms CAFs and myeloid cells into antitumor immune agonists in PDAC, supporting the validation of such effects in human specimens.